{{Rsnum
|rsid=4799915
|Gene=CELF4
|Chromosome=18
|position=37348676
|Orientation=plus
|GMAF=0.4008
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CELF4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 13.3 | 46.0 | 40.7
| HCB | 9.5 | 36.5 | 54.0
| JPT | 7.1 | 31.9 | 61.1
| YRI | 55.8 | 37.4 | 6.8
| ASW | 42.1 | 50.9 | 7.0
| CHB | 9.5 | 36.5 | 54.0
| CHD | 4.6 | 45.0 | 50.5
| GIH | 17.8 | 42.6 | 39.6
| LWK | 45.5 | 41.8 | 12.7
| MEX | 5.2 | 43.1 | 51.7
| MKK | 27.1 | 49.0 | 23.9
| TSI | 10.8 | 49.0 | 40.2
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs4799915
|PubMedID=18521091
|Condition=Response to iloperidone treatment (QT prolongation)
|Gene=BRUNOL4
|Risk Allele=T
|pValue=3.00E-006
|OR=NA
|95CI=
}}

{{PharmGKB
|RSID=rs4799915
|Name_s=
|Gene_s=BRUNOL4
|Feature=
|Evidence=PubMed ID:18521091; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS Results: Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia (Initial Sample Size: 183 individuals; Replication Sample Size: NR; Risk Allele: rs4799915-T). This variant is associated with Response to iloperidone treatment (QT prolongation).
|Drugs=iloperidone
|Drug Classes=
|Diseases=Acquired Long QT Syndrome (aLQTS); congenital long QT syndrome; Long QT Syndrome
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356589
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4799915
|overall_frequency_n=71
|overall_frequency_d=128
|overall_frequency=0.554688
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}